EMA

EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca

Gilead's Tecartus Gets EMA CHMP Recommendation in Advanced ALL

Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma

Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer

EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients

In Brief This Week: Helio Genomics, BeiGene, Day One, Mustang Bio, Ikena Oncology, Strata Oncology

BMS Submits Breyanzi for European Approval as Second-Line Lymphoma Treatment

Medac, Byondis Strike Commercialization Pact for HER2-Targeted Antibody-Drug Conjugate

Janssen Seeking European Union Approval for Zejula in HRR-Positive Prostate Cancer

NewStem Files FDA De Novo Submission, Gets CE Mark for Stem Cell Mutational Analysis Software

In Brief This Week: Taiho Oncology, PamGene, Mursla, Autolus Therapeutics, Clovis Oncology

EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers

EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in Specific MSI-H/dMMR Tumors

EMA's CHMP Issues Positive Recommendations for Novartis' Kymriah, Janssen's Carvykti

CHMP Recommends Approval for Opdivo in PD-L1-Positive Esophageal, Urothelial Cancers

CHMP Issues Positive Opinion for Immunocore's Kimmtrak as Metastatic Uveal Melanoma Treatment

EMA's CHMP Issues Positive Opinion on BMS' Breyanzi for Lymphoma Patients

EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer

EMA's CHMP Issues Positive Opinion on Merck KGaA's Tepmetko for Lung Cancer Subgroup

EMA Accepts Marketing Application for Atara Biotherapeutics' Tabelecleucel